Pharmaceutical Technology Europe, Nov 1, 2010 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Nov 1, 2010
Special Feature
Packaging: The Experts' View
By Carsten Peters , Piero Tomasi , Giuseppe Cardini , Agostino Consolini , Franz Ludwig , Jürgen Schafer
Leading European experts from the pharmaceutical packaging industry explain how they are coping with industry trends.
Is Pharma Doing Enough To reduce The Environmental Impact Of packaging?
By Jon Wear
Generally, the pharma industry isn't doing enough to reduce the environmental impact of its packaging materials, but there are various historic reasons for this.
Designing An Effective PAT-Driven Scale-Up Of Lyophilization Processes
By Maik Guttzeit
This article examines the difficulties in designing lyophilisation processes that can be faithfully scaled up to production volumes and suggests the most effective ways in which this can be achieved.
Dissolution Testing For Inhaled drugs
By Mark Copley , Yoen-Ju Son , Jason McConville
Although there are no regulatory requirements or established pharmacopoeial techniques for the dissolution testing of inhaled drugs, such testing can potentially open up the opportunity to tailor formulation properties.
Overcoming The Challenges Of Cell-Based BioProcessing
By Erika Lapinskas
Discussing the key challenges that face cell-based bioprocess manufacturers today, how these challenges might be addressed and the innovations that could facilitate the process in the future.
Industry Insider
Will Transatlantic Regulatory Cooperation Meet Expectations?
By Nathan Jessop
There has been increasing cooperation between the EMA and the FDA in recent years, and this looks set to continue in the future.
Joint regulatory API inspections on the rise.
Editor's Comment
Lessons in efficiency
By Fedra Pavlou
I recently attended the annual CPhI exhibition in Paris, which turned out to be a great event for the PTE team and I.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here